RNF34

RNF34 is a RING-finger E3 ubiquitin ligase that negatively regulates innate immune signaling, energy metabolism, synaptic receptor homeostasis, and peripheral protein quality control by ubiquitinating distinct substrates and directing them to proteasomal or autophagic degradation. In antiviral innate immunity, RNF34 catalyzes K27- and K29-linked polyubiquitination of MAVS, creating a recognition signal for NDP52/TAX1BP1-dependent autophagic clearance of MAVS and damaged mitochondria, thereby restraining RIG-I signaling and NLRP3 inflammasome activation (PMID:31304625, PMID:36654301). RNF34 ubiquitinates PGC-1α via its C-terminal half to promote proteasomal degradation, suppressing UCP1 expression, mitochondrial biogenesis, and thermogenesis in brown adipocytes—a pathway conserved in Drosophila muscle where dRNF34 limits exercise capacity and fat metabolism (PMID:22064484, PMID:30247505). Additional substrates include the GABAAR γ2 subunit (promoting synaptic receptor turnover in hippocampal neurons) (PMID:25193658), NOD1 (dampening NF-κB activation) (PMID:25012219), p22phox (limiting NADPH oxidase complex assembly and ROS production in vascular smooth muscle) (PMID:34015492), and misfolded CFTR NBD1 (peripheral quality control of ΔF508-CFTR at cytoplasm/endosomes) (PMID:35355508).

1. 2011 High

   Identification of RNF34 as an E3 ligase for PGC-1α established the first physiological substrate and linked RNF34 to energy metabolism and thermogenesis, showing that RNF34-mediated ubiquitination targets PGC-1α for proteasomal degradation independently of the known N-terminal phosphodegron.

   Evidence Luciferase overexpression screen, Co-IP, in vitro ubiquitination, ligase-dead mutant, RNAi in brown fat cells with UCP1 and O₂ consumption readouts

   PMID:22064484

   Open questions at the time

   • Structural basis for RNF34 recognition of the PGC-1α C-terminal half unknown
   • E2 enzyme specificity for this reaction not identified
   • In vivo significance in whole-animal energy homeostasis not yet tested with genetic knockout
2. 2014 High

   Discovery of two additional substrates—GABAAR γ2 subunit and NOD1—expanded RNF34's functional repertoire to synaptic receptor turnover and innate immune signaling, demonstrating that RNF34 promotes lysosomal/proteasomal degradation of γ2 to reduce GABAergic synapse density and ubiquitinates NOD1 to dampen NF-κB signaling.

   Evidence Yeast two-hybrid, reciprocal Co-IP from brain extracts, lysine mutagenesis, shRNA in hippocampal neurons, and GST-pulldown/NF-κB reporter assays for NOD1

   PMID:25012219 PMID:25193658

   Open questions at the time

   • Ubiquitin chain type on γ2 and NOD1 not determined
   • In vivo neuronal phenotype of RNF34 loss not examined
   • NOD1 finding from single lab without independent replication
3. 2018 Medium

   Cross-species validation in Drosophila confirmed that PGC-1 is a conserved RNF34 substrate, and genetic epistasis demonstrated that dRNF34 restrains mitochondrial biogenesis and exercise capacity in a PGC-1-dependent manner.

   Evidence Muscle-specific dRNF34 RNAi in Drosophila with Co-IP, climbing endurance, triglyceride assays, and dPGC-1 KD rescue

   PMID:30247505

   Open questions at the time

   • Whether tissue-specific regulation parallels mammalian brown fat pathway not directly tested
   • Direct ubiquitination of dPGC-1 by dRNF34 not reconstituted in vitro with purified proteins
4. 2019 High

   Mechanistic dissection of MAVS ubiquitination revealed that RNF34 catalyzes K27/K29-linked chains on specific lysines of MAVS to create an NDP52-dependent autophagic degradation signal, and orchestrates a K63-to-K27 ubiquitin-chain editing event, establishing RNF34 as a key negative regulator of RIG-I antiviral signaling and virus-induced mitophagy.

   Evidence Site-directed mutagenesis of MAVS lysines, chain-type-specific ubiquitination assays, autophagy flux, viral infection models

   PMID:31304625

   Open questions at the time

   • Identity of the K63 ligase whose chains are edited by RNF34 not determined
   • Whether RNF34 directly deubiquitinates K63 chains or recruits a DUB is unresolved
   • In vivo antiviral phenotype in RNF34-knockout mice not reported
5. 2019 Medium

   An in vivo transgenic mouse model confirmed that RNF34 overexpression degrades PGC-1α in brain tissue and worsens mitochondrial dysfunction and oxidative stress after intracerebral hemorrhage, linking the PGC-1α axis to neurological injury.

   Evidence RNF34 transgenic mice, ICH model, Co-IP, ubiquitination assay, ROS/ATP measurement

   PMID:31704983

   Open questions at the time

   • Gain-of-function model only; loss-of-function not tested in this context
   • Whether effects are solely PGC-1α-dependent not established by rescue
6. 2021 High

   Identification of p22phox as a substrate in vascular smooth muscle, using conditional knockout mice, demonstrated that RNF34 restricts NADPH oxidase complex assembly and ROS production in vivo, with loss of RNF34 driving cerebrovascular remodeling and hypertension.

   Evidence SMC-specific RNF34 conditional KO, Co-IP, ubiquitination assay, superoxide/ROS measurement, p22phox KD rescue

   PMID:34015492

   Open questions at the time

   • Ubiquitin chain type on p22phox not characterized
   • Whether RNF34 regulates other NOX subunits directly not tested
7. 2021 Medium

   TAX1BP1 was identified as a recruiter of RNF34 to MAVS, and RNF34 was shown to be essential for TAX1BP1-mediated protection against hypoxia-induced MAVS accumulation and NLRP3 inflammasome activation in cardiomyocytes, broadening the RNF34-MAVS axis to sterile inflammation.

   Evidence Co-IP, siRNA KD of RNF34, NLRP3 inflammasome activation assay in cardiomyocytes

   PMID:36654301

   Open questions at the time

   • TAX1BP1–RNF34 direct binding interface not mapped
   • Whether TAX1BP1 and NDP52 act redundantly or sequentially in RNF34-dependent MAVS clearance not resolved
8. 2022 High

   RNF34 was shown to directly recognize the CFTR NBD1 domain and selectively ubiquitinate misfolded CFTR in the peripheral quality control pathway; combined ablation of RNF34 and RFFL dramatically rescued ΔF508-CFTR plasma membrane expression, revealing a therapeutic vulnerability in cystic fibrosis.

   Evidence In vitro ubiquitination with purified NBD1, subcellular fractionation, CFTR-NLuc degradation assay, dual siRNA KD, flow cytometry

   PMID:35355508

   Open questions at the time

   • Structural basis for NBD1 unfolding recognition by RNF34 not resolved
   • In vivo relevance of RNF34/RFFL dual inhibition for CFTR modulator therapy not tested

• A unifying structural and regulatory model for how RNF34 selects among its diverse substrates, the E2 enzymes it employs for different chain types, and its own regulation (transcriptional, post-translational) under physiological stress remains incomplete.
• No crystal or cryo-EM structure of RNF34 or any RNF34–substrate complex exists
• E2 partners for K27/K29/K48 chain formation have not been identified
• Transcriptional regulation beyond β3-adrenergic repression is uncharacterized
• Global RNF34 knockout mouse phenotype not reported